Roche beats Q3 forecasts on Ocrevus, accelerates external deals as patents expire

Roche reported quarterly revenue above expectations, driven by strong Ocrevus sales, while intensifying its search for external partnerships to offset upcoming patent expirations. The company's strategic pivot toward M&A and licensing signals urgency to replenish its pipeline, though the success of this approach remains uncertain.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works